uPA Cancer Research Results

uPA, Urokinase plasminogen activator: Click to Expand ⟱
Source:
Type:
uPA (urokinase plasminogen activator) is a serine protease that plays a crucial role in the conversion of plasminogen to plasmin, an enzyme responsible for degrading various components of the extracellular matrix (ECM). This activity is central to processes such as tissue remodeling, cell migration, and angiogenesis. In the context of cancer, uPA facilitates tumor invasion and metastasis by promoting ECM degradation, while its interaction with its receptor (uPAR) and inhibitors (such as PAI-1) forms a regulatory axis that is frequently dysregulated in malignancies.

Patients with higher pretreatment serum uPA (≥1 ng/ml) had significantly shorter OS.

Elevated uPA expression has been observed in a broad range of cancers, including breast, colorectal, lung, and prostate cancers. These high levels are often indicative of increased proteolytic activity within the tumor microenvironment.
Tumors with aggressive behavior often exhibit upregulation of uPA, along with its receptor uPAR. This upregulation enhances plasmin generation and leads to an environment conducive to invasion and metastasis.

Elevated uPA levels in tumor tissues have been strongly associated with poor clinical outcomes. High uPA expression is correlated with increased risk of metastasis, higher likelihood of recurrence, and reduced overall survival in several cancer types.
Var, Various Cancer: Click to Expand ⟱
Cyclooxygenase (COX)-2 overexpression has been noted in various cancers. PI3Ks/AKT pathways are over-activated in several types of cancers.
EGFR altered activity has been noted in various pathological conditions. However, its regulation is an important step in the inhibition of cancer. In this regard, EGCG shows a pivotal role in the inhibition of EGFR activity.
Activating protein-1 transcription factor has been associated with pathogenesis including cancer.
Activation of the sonic hedgehog (Shh) pathway is required for the growth of numerous tissues and organs and recent evidence indicates that this pathway is often recruited to stimulate growth of cancer stem cells (CSCs) and to orchestrate the reprogramming of cancer cells via epithelial mesenchymal transition (EMT). Increased expression of Nanog has been associated with the aggressive nature of certain cancers, highlighting its role in promoting cancer stem cell characteristics.
The aberrant hedgehog (Hh)/GLI signaling pathway causes the formation and progression of a variety of tumors.
The process of cell apoptosis is often accompanied by the destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis.
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses50.
Several studies have demonstrated that high cyclin D1 expression was observed in cancers including breast, lung, prostate, lymph node and colorectal cancers [23–25].
The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell.
Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.
Heat shock proteins (HSPs) are normally induced under environmental stress to serve as chaperones for maintenance of correct protein folding but they are often overexpressed in many cancers, including breast cancer.
Since NQO1 is highly expressed in many solid tumors, including via upregulation of Nrf2, the design of compounds activated by NQO1 and NQO1-targeted drug delivery have been active areas of research.
Since increased Nrf2 gene expression is one of the main mechanisms of cancer cells in resisting chemotherapeutic drugs and survival in oxidative conditions; finding compounds with the ability to suppress Nrf2 gene expression with minimum side effects can be considered an important strategy for increasing the sensitivity of cancer cells to chemotherapy.
Overexpression of c-met stimulates proliferation, migration and invasion in various types of cancer including prostate cancer.
Overexpression of TGFα and EGFR by many carcinomas correlates with the development of cancer metastasis, resistance to chemotherapy and poor prognosis.
More than 50% of human cancers have a mutated nonfunctional p53.


Scientific Papers found: Click to Expand⟱
2639- Api,    Plant flavone apigenin: An emerging anticancer agent
- Review, Var, NA
*antiOx↑, *Inflam↓, AntiCan↑, ChemoSen↑, BioEnh↑, chemoPv↑, IL6↓, STAT3↓, NF-kB↓, IL8↓, eff↝, Akt↓, PI3K↓, HER2/EBBR2↓, cycD1/CCND1↓, CycD3↓, p27↑, FOXO3↑, STAT3↓, MMP2↓, MMP9↓, VEGF↓, Twist↓, MMP↓, ROS↑, NADPH↑, NRF2↓, SOD↓, COX2↓, p38↑, Telomerase↓, HDAC↓, HDAC1↓, HDAC3↓, Hif1a↓, angioG↓, uPA↓, Ca+2↑, Bax:Bcl2↑, Cyt‑c↑, Casp9↑, Casp12↑, Casp3↑, cl‑PARP↑, E-cadherin↑, β-catenin/ZEB1↓, cMyc↓, CDK4↓, CDK2↓, CDK6↓, IGF-1↓, CK2↓, CSCs↓, FAK↓, Gli↓, GLUT1↓,
3382- ART/DHA,    Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
- Review, Var, NA
AntiCan↑, toxicity↑, Ferroptosis↑, ROS↑, TumCCA↑, BioAv↝, eff↝, Half-Life↓, Ferritin↓, GPx4↓, NADPH↓, GSH↓, BAX↑, Cyt‑c↑, cl‑Casp3↑, VEGF↓, IL8↓, COX2↓, MMP9↓, E-cadherin↑, MMP2↓, NF-kB↓, p16↑, CDK4↓, cycD1/CCND1↓, p62↓, LC3II↑, EMT↓, CSCs↓, Wnt↓, β-catenin/ZEB1↓, uPA↓, TumAuto↑, angioG↓, ChemoSen↑,
3383- ART/DHA,    Dihydroartemisinin: A Potential Natural Anticancer Drug
- Review, Var, NA
TumCP↓, Apoptosis↑, TumMeta↓, angioG↓, TumAuto↑, ER Stress↑, ROS↑, Ca+2↑, p38↑, HSP70/HSPA5↓, PPARγ↑, GLUT1↓, Glycolysis↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, lactateProd↓, GlucoseCon↓, EMT↓, Slug↓, Zeb1↓, ZEB2↓, Twist↓, Snail?, CAFs/TAFs↓, TGF-β↓, p‑STAT3↓, M2 MC↓, uPA↓, HH↓, AXL↓, VEGFR2↓, JNK↑, Beclin-1↑, GRP78/BiP↑, eff↑, eff↑, eff↑, eff↑, eff↑, eff↑, IL4↓, DR5↑, Cyt‑c↑, Fas↑, FADD↑, cl‑PARP↑, cycE/CCNE↓, CDK2↓, CDK4↓, Mcl-1↓, Ki-67↓, Bcl-2↓, CDK6↓, VEGF↓, COX2↓, MMP9↓,
3391- ART/DHA,    Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug
- Review, Var, NA
TumCP↓, TumMeta↓, angioG↓, TumVol↓, BioAv↓, Half-Life↓, BioAv↑, eff↑, eff↓, ROS↑, selectivity↑, TumCCA↑, survivin↓, BAX↑, Casp3↓, Casp8↑, Casp9↑, CDC25↓, CycB/CCNB1↓, NF-kB↓, cycD1/CCND1↓, cycE/CCNE↓, E2Fs↓, P21↑, p27↑, ADP:ATP↑, MDM2↓, VEGF↓, IL8↓, COX2↓, MMP9↓, ER Stress↓, cMyc↓, GRP78/BiP↑, DNAdam↑, AP-1↓, MMP2↓, PKCδ↓, Raf↓, ERK↓, JNK↓, PCNA↓, CDK2↓, CDK4↓, TOP2↓, uPA↓, MMP7↓, TIMP2↑, Cdc42↑, E-cadherin↑,
3156- Ash,    Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug
- Review, Var, NA
MAPK↑, p38↑, BAX↑, BIM↑, CHOP↑, ROS↑, DR5↑, Apoptosis↑, Ferroptosis↑, GPx4↓, BioAv↝, HSP90↓, RET↓, E6↓, E7↓, Akt↓, cMET↓, Glycolysis↓, TCA↓, NOTCH1↓, STAT3↓, AP-1↓, PI3K↓, eIF2α↓, HO-1↑, TumCCA↑, CDK1↓, *hepatoP↑, *GSH↑, *NRF2↑, Wnt↓, EMT↓, uPA↓, CSCs↓, Nanog↓, SOX2↓, CD44↓, lactateProd↓, Iron↑, NF-kB↓,
3160- Ash,    Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal
- Review, Var, NA
TumCCA↑, H3↑, P21↑, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, CDC2↓, CHK1↓, Chk2↓, p38↑, MAPK↑, E6↓, E7↓, P53↑, Akt↓, FOXO3↑, ROS↑, γH2AX↑, MMP↓, mitResp↓, eff↑, TumCD↑, Mcl-1↓, ER Stress↑, ATF4↑, ATF3↑, CHOP↑, NOTCH↓, NF-kB↓, Bcl-2↓, STAT3↓, CDK1↓, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, Cyt‑c↑, eff↑, CDK4↓, p‑RB1↓, PARP↑, cl‑Casp3↑, cl‑Casp9↑, NRF2↑, ER-α36↓, LDHA↓, lipid-P↑, AP-1↓, COX2↓, RenoP↑, PDGFR-BB↓, SIRT3↑, MMP2↓, MMP9↓, NADPH↑, NQO1↑, GSR↑, HO-1↑, *SOD2↑, *Prx↑, *Casp3?, eff↑, Snail↓, Slug↓, Vim↓, CSCs↓, HEY1↓, MMPs↓, VEGF↓, uPA↓, *toxicity↓, CDK2↓, CDK4↓, HSP90↓,
2617- Ba,    Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review
- Review, Var, NA
Ca+2↑, MMP2↓, MMP9↓, Vim↓, Snail↓, E-cadherin↑, Wnt↓, β-catenin/ZEB1↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, i-ROS↑, Bcl-2↓, BAX↑, Cyt‑c↑, Casp3↑, Casp9↑, STAT3↓, IL6↓, MMP2↓, MMP9↓, NOTCH↓, PPARγ↓, p‑NRF2↓, HK2↓, LDHA↓, PDK1↓, Glycolysis↓, PTEN↑, Akt↓, Hif1a↓, MMP↓, VEGF↓, VEGFR2↓, TOP2↓, uPA↓, TIMP1↓, TIMP2↓, cMyc↓, TrxR↓, ASK1↑, Vim↓, ZO-1↑, E-cadherin↑, SOX2↓, OCT4↓, Shh↓, Smo↓, Gli1↓, N-cadherin↓, XIAP↓,
2674- BBR,    Berberine: A novel therapeutic strategy for cancer
- Review, Var, NA - Review, IBD, NA
Inflam↓, AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, TumCI↓, eff↑, eff↑, CD4+↓, TNF-α↓, IL1↓, BioAv↓, BioAv↓, other↓, AMPK↑, MAPK↓, NF-kB↓, IL6↓, MCP1↓, PGE2↓, COX2↓, *ROS↓, *antiOx↑, *GPx↑, *Catalase↑, AntiTum↑, TumCP↓, angioG↓, Fas↑, FasL↑, ROS↑, ATM↑, P53↑, RB1↑, Casp9↑, Casp8↑, Casp3↓, BAX↑, Bcl-2↓, Bcl-xL↓, IAP1↓, XIAP↓, survivin↓, MMP2↓, MMP9↓, CycB/CCNB1↓, CDC25↓, CDC25↓, Cyt‑c↑, MMP↓, RenoP↑, mTOR↓, MDM2↓, LC3II↑, ERK↓, COX2↓, MMP3↓, TGF-β↓, EMT↑, ROCK1↓, FAK↓, RAS↓, Rho↓, NF-kB↓, uPA↓, MMP1↓, MMP13↓, ChemoSen↑,
2781- CHr,  PBG,    Chrysin a promising anticancer agent: recent perspectives
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, MMP9↑, uPA↓, VEGF↓, AR↓, Casp↑, TumMeta↓, TumCCA↑, angioG↓, BioAv↓, *hepatoP↑, *neuroP↑, *SOD↑, *GPx↑, *ROS↓, *Inflam↓, *Catalase↑, *MDA↓, ROS↓, BBB↑, Half-Life↓, BioAv↑, ROS↑, eff↑, ROS↑, ROS↑, lipid-P↑, ER Stress↑, NOTCH1↑, NRF2↓, p‑FAK↓, Rho↓, PCNA↓, COX2↓, NF-kB↓, PDK1↓, PDK3↑, GLUT1↓, Glycolysis↓, mt-ATP↓, Ki-67↓, cMyc↓, ROCK1↓, TOP1↓, TNF-α↓, IL1β↓, CycB/CCNB1↓, CDK2↓, EMT↓, STAT3↓, PD-L1↓, IL2↑,
3238- EGCG,    Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications
- Review, Var, NA
Telomerase↓, DNMTs↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, HATs↓, HDAC↓, selectivity↑, uPA↓, NF-kB↓, TNF-α↓, *ROS↓, *antiOx↑, Hif1a↓, VEGF↓, MMP2↓, MMP9↓, FAK↓, TIMP2↑, Mcl-1↓, survivin↓, XIAP↓, PCNA↓, p16↑, P21↑, p27↑, pRB↑, P53↑, MDM2↑, ROS↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Diablo↑, BAX⇅, cl‑PPARα↓, PDGF↓, EGFR↓, FOXO↑, AP-1↓, JNK↓, COX2↓, angioG↓,
2857- FIS,    A review on the chemotherapeutic potential of fisetin: In vitro evidences
- Review, Var, NA
COX2↓, PGE2↓, EGFR↓, Wnt↓, β-catenin/ZEB1↓, TCF↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, Akt↓, mTOR↓, ACC↑, Cyt‑c↑, Diablo↑, cl‑Casp8↑, Fas↑, DR5↑, TRAIL↑, Securin↓, CDC2↓, CDC25↓, HSP70/HSPA5↓, CDK2↓, CDK4↓, cycD1/CCND1↓, MMP2↓, uPA↓, NF-kB↓, cFos↓, cJun↓, MEK↓, p‑ERK↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↓, NF-kB↑, ROS↑, DNAdam↑, MMP↓, CHOP↑, eff↑, ChemoSen↑,
2845- FIS,    Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, p38↓, *antiOx↑, *neuroP↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, DNAdam↑, MMP↓, eff↑, ROS↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, P53↑, p65↓, Myc↓, HSP70/HSPA5↓, HSP27↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycA1/CCNA1↓, P21↑, MMP2↓, MMP9↓, TumMeta↓, MMP1↓, MMP3↓, MMP7↓, MET↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↑, uPA↓, ChemoSen↑, EMT↓, Twist↓, Zeb1↓, cFos↓, cJun↓, EGF↓, angioG↓, VEGF↓, eNOS↓, *NRF2↑, HO-1↑, NRF2↓, GSTs↓, ATF4↓,
2824- FIS,    Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
- Review, Var, NA
*antiOx↑, *Inflam↓, angioG↓, BioAv↓, BioAv↑, TumCP↓, TumCI↓, TumCMig↓, *neuroP↑, EMT↓, ROS↑, selectivity↑, EGFR↓, NF-kB↓, VEGF↓, MMP9↓, MMP↓, cl‑PARP↑, Casp7↑, Casp8↑, Casp9↑, *ROS↓, uPA↓, MMP1↓, Wnt↓, Akt↓, PI3K↓, ERK↓, Half-Life↝,
2825- FIS,    Exploring the molecular targets of dietary flavonoid fisetin in cancer
- Review, Var, NA
*Inflam↓, *antiOx↓, *ERK↑, *p‑cMyc↑, *NRF2↑, *GSH↑, *HO-1↑, mTOR↓, PI3K↓, Akt↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27↑, JNK↑, MMP2↓, MMP9↓, uPA↓, NF-kB↓, cFos↓, cJun↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, MMP↓, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, P53↑, COX2↓, PGE2↓, HSP70/HSPA5↓, HSP27↓, DNAdam↑, Casp3↑, Casp9↑, ROS↑, AMPK↑, NO↑, Ca+2↑, mTORC1↓, p70S6↓, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, eff↑, eff↑, eff↑, RadioS↑, ChemoSen↑, Half-Life↝,
2827- FIS,    The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, neuroP↑, hepatoP↑, RenoP↑, cycD1/CCND1↓, TumCCA↑, MMPs↓, VEGF↓, MAPK↓, NF-kB↓, angioG↓, Beclin-1↑, LC3s↑, ATG5↑, Bcl-2↓, BAX↑, Casp↑, TNF-α↓, Half-Life↓, MMP↓, mt-ROS↑, cl‑PARP↑, CDK2↓, CDK4↓, Cyt‑c↑, Diablo↑, DR5↑, Fas↑, PCNA↓, Ki-67↓, p‑H3↓, chemoP↑, Ca+2↑, Dose↝, CDC25↓, CDC2↓, CHK1↑, Chk2↑, ATM↑, PCK1↓, RAS↓, p‑p38↓, Rho↓, uPA↓, MMP7↓, MMP13↓, GSK‐3β↑, E-cadherin↑, survivin↓, VEGFR2↓, IAP2↓, STAT3↓, JAK1↓, mTORC1↓, mTORC2↓, NRF2↑,
2828- FIS,    Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review
- Review, Var, NA
*neuroP↑, *antiOx↑, *Inflam↓, RenoP↑, COX2↓, Wnt↓, EGFR↓, NF-kB↓, Casp3↑, Ca+2↑, Casp8↑, TumCCA↑, CDK1↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, *P53↓, *P21↓, *p16↓, mTORC1↓, mTORC2↓, P53↑, P21↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, BAX↑, Bcl-2↓, PCNA↓, HER2/EBBR2↓, Cyt‑c↑, MMP↓, cl‑Casp9↑, MMP2↓, MMP9↓, cl‑PARP↑, uPA↓, DR4↑, DR5↑, ROS↓, AIF↑, CDC25↓, Dose↑, CHOP↑, ROS↑, cMyc↓, cardioP↑,
2829- FIS,    Fisetin: An anticancer perspective
- Review, Var, NA
TumCP↓, TumCI↓, TumCCA↑, TumCG↓, Apoptosis↑, cl‑PARP↑, PKCδ↓, ROS↓, ERK↓, NF-kB↓, survivin↓, ROS↑, PI3K↓, Akt↓, mTOR↓, MAPK↓, p38↓, HER2/EBBR2↓, EMT↓, PTEN↑, HO-1↑, NRF2↑, MMP2↓, MMP9↓, MMP↓, Casp8↑, Casp9↑, TRAILR↑, Cyt‑c↑, XIAP↓, P53↑, CDK2↓, CDK4↓, CDC25↓, CDC2↓, VEGF↓, DNAdam↑, TET1↓, CHOP↑, CD44↓, CD133↓, uPA↓, CSCs↓,
2830- FIS,    Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent
- Review, Var, NA
TumCG↓, angioG↓, *ROS↓, TumCMig↓, VEGF↓, MAPK↑, NF-kB↓, PI3K↓, Akt↓, mTOR↓, NRF2↑, HO-1↑, ROS↓, Inflam↓, ER Stress↑, ROS↑, TumCP↓, ChemoSen↑, PTEN↑, P53↑, Casp3↑, Casp8↑, Casp9↑, COX2↓, Wnt↓, EGFR↓, Mcl-1↓, survivin↓, IAP1↓, IAP2↓, PGE2↓, β-catenin/ZEB1↓, DR5↑, MMP2↓, MMP9↓, FAK↓, uPA↓, EMT↓, ERK↓, JNK↑, p38↑, PKCδ↓, BioAv↓, BioAv↑, BioAv↑,
2839- FIS,    Dietary flavonoid fisetin for cancer prevention and treatment
- Review, Var, NA
DNAdam↑, ROS↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp9↑, cl‑Casp3↑, Cyt‑c↑, lipid-P↓, TumCG↓, TumCA↓, TumCMig↓, TumCI↓, uPA↓, ERK↓, MMP9↓, NF-kB↓, cFos↓, cJun↓, AP-1↓, TumCCA↑, AR↓, mTORC1↓, mTORC2↓, TSC2↑, EGF↓, TGF-β↓, EMT↓, P-gp↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, ChemoSen↑, CDK2↓, CDK4↓, cycE/CCNE↓, cycD1/CCND1↓, P21↑, COX2↓, Wnt↓, EGFR↓, β-catenin/ZEB1↓, TCF-4↓, MMP7↓, RadioS↑, eff↑,
2832- FIS,    Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies
- Review, Var, NA
MMP↓, mtDam↑, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, Bak↑, BIM↑, Bcl-xL↓, Bcl-2↓, P53↑, ROS↑, AMPK↑, Casp9↑, Casp3↑, BID↑, AIF↑, Akt↓, mTOR↓, MAPK↓, Wnt↓, β-catenin/ZEB1↓, TumCCA↑, P21↑, p27↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, TumMeta↓, uPA↓, E-cadherin↑, Vim↓, EMT↓, Twist↓, DNAdam↑, ROS↓, COX2↓, PGE2↓, HSF1↓, cFos↓, cJun↓, AP-1↓, Mcl-1↓, NF-kB↓, IRE1↑, ER Stress↑, ATF4↑, GRP78/BiP↑, MMP2↓, MMP9↓, TCF-4↓, MMP7↓, RadioS↑, TOP1↓, TOP2↓,
2998- GEN,    Cellular and Molecular Mechanisms Modulated by Genistein in Cancer
- Review, Var, NA
Hif1a↓, VEGF↓, PDGF↓, uPA↓, MMP2↓, MMP9↓, chemoPv↑, TumCI↓, TumMeta↓, NF-kB↓, AP-1↓, IKKα↓, PI3K↓, Akt↓, EMT↓, CSCs↓,
4519- MAG,    Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer
- Review, Var, NA
*antiOx↑, *Inflam↓, *Bacteria↓, *AntiAg↑, *BBB↑, *BioAv↓, BAD↑, Casp3↑, Casp6↑, Casp9↑, JNK↑, Bcl-xL↓, PTEN↑, Akt↓, NF-kB↓, MMP7↓, MMP9↓, uPA↓, Hif1a↓, VEGF↓, FOXO3↓, Ca+2↑, TumCCA↑, ROS↑, Cyt‑c↑,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2↓, cFLIP↓, cycD1/CCND1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, eff↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, eff↑, eff↑, eff↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,

Showing Research Papers: 1 to 25 of 25

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 25

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ATF3↑, 1,   Ferroptosis↑, 2,   GPx4↓, 2,   GSH↓, 1,   GSH↑, 1,   GSR↑, 1,   GSTs↓, 1,   HO-1↑, 5,   Iron↑, 1,   lipid-P↓, 2,   lipid-P↑, 2,   NQO1↑, 1,   NRF2↓, 4,   NRF2↑, 4,   p‑NRF2↓, 1,   ROS↓, 8,   ROS↑, 23,   i-ROS↑, 1,   mt-ROS↑, 1,   SIRT3↑, 1,   SOD↓, 1,   TrxR↓, 1,  

Metal & Cofactor Biology ⓘ

Ferritin↓, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↑, 1,   AIF↑, 2,   mt-ATP↓, 1,   CDC2↓, 4,   CDC25↓, 7,   EGF↓, 2,   MEK↓, 2,   mitResp↓, 1,   MMP↓, 14,   mtDam↑, 1,   Raf↓, 2,   XIAP↓, 4,  

Core Metabolism/Glycolysis ⓘ

ACC↑, 2,   AMPK↑, 4,   cMyc↓, 7,   GlucoseCon↓, 1,   Glycolysis↓, 4,   HK2↓, 1,   lactateProd↓, 2,   LDHA↓, 2,   NADPH↓, 1,   NADPH↑, 2,   PCK1↓, 1,   PDK1↓, 2,   PDK3↑, 1,   PKM2↓, 2,   cl‑PPARα↓, 1,   PPARγ↓, 1,   PPARγ↑, 1,   TCA↓, 1,  

Cell Death ⓘ

Akt↓, 19,   p‑Akt↓, 2,   APAF1↑, 1,   Apoptosis↑, 6,   ASK1↑, 1,   BAD↑, 3,   Bak↑, 1,   BAX↑, 13,   BAX⇅, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 12,   Bcl-xL↓, 4,   BID↑, 1,   BIM↓, 1,   BIM↑, 4,   Casp↑, 5,   Casp12↑, 1,   Casp3↓, 3,   Casp3↑, 13,   cl‑Casp3↑, 3,   Casp6↑, 1,   Casp7↑, 2,   Casp8↑, 7,   cl‑Casp8↑, 1,   Casp9↑, 13,   cl‑Casp9↑, 3,   cFLIP↓, 1,   Chk2↓, 1,   Chk2↑, 1,   CK2↓, 1,   Cyt‑c↑, 18,   Diablo↑, 7,   DR4↑, 1,   DR5↑, 6,   FADD↑, 1,   Fas↑, 4,   FasL↑, 1,   Ferroptosis↑, 2,   HEY1↓, 1,   IAP1↓, 2,   IAP2↓, 2,   iNOS↓, 1,   JNK↓, 2,   JNK↑, 4,   MAPK↓, 6,   MAPK↑, 3,   Mcl-1↓, 7,   MDM2↓, 2,   MDM2↑, 1,   Myc↓, 2,   p27↑, 5,   p38↓, 2,   p38↑, 5,   p‑p38↓, 1,   RIP1↑, 1,   survivin↓, 7,   Telomerase↓, 2,   TRAIL↑, 2,   TRAILR↑, 1,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 3,   p70S6↓, 1,   RET↓, 1,   TSC2↑, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 5,   H3↑, 1,   p‑H3↓, 1,   ac‑H3↑, 1,   ac‑H4↑, 1,   HATs↓, 1,   HATs↑, 1,   other↓, 1,   pRB↑, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 5,   eIF2α↓, 1,   ER Stress↓, 1,   ER Stress↑, 8,   GRP78/BiP↑, 5,   HSF1↓, 1,   HSP27↓, 2,   HSP70/HSPA5↓, 4,   HSP90↓, 2,   IRE1↑, 3,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 2,   LC3II↑, 3,   LC3s↑, 1,   p62↓, 1,   TumAuto↑, 3,  

DNA Damage & Repair ⓘ

ATM↑, 2,   CHK1↓, 1,   CHK1↑, 1,   DFF45↓, 1,   DNAdam↑, 7,   DNMT1↓, 1,   DNMTs↓, 2,   p16↑, 2,   P53↑, 12,   PARP↑, 1,   cl‑PARP↑, 10,   PARP1↑, 1,   PCNA↓, 7,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 3,   CDK2↓, 14,   CDK4↓, 15,   cycA1/CCNA1↓, 3,   CycB/CCNB1↓, 4,   cycD1/CCND1↓, 13,   CycD3↓, 1,   cycE/CCNE↓, 7,   E2Fs↓, 1,   P21↓, 1,   P21↑, 8,   RB1↑, 1,   p‑RB1↓, 1,   Securin↓, 1,   TumCCA↑, 15,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD44↓, 2,   cFos↓, 5,   cMET↓, 1,   CSCs↓, 6,   EMT↓, 16,   EMT↑, 1,   ERK↓, 7,   p‑ERK↓, 2,   FOXO↑, 1,   FOXO3↓, 1,   FOXO3↑, 2,   Gli↓, 1,   Gli1↓, 1,   GSK‐3β↑, 1,   HDAC↓, 4,   HDAC1↓, 1,   HDAC3↓, 1,   HH↓, 1,   IGF-1↓, 1,   mTOR↓, 12,   p‑mTOR↓, 2,   mTORC1↓, 4,   mTORC2↓, 3,   Nanog↓, 1,   NOTCH↓, 2,   NOTCH1↓, 1,   NOTCH1↑, 1,   OCT4↓, 1,   PI3K↓, 14,   PTEN↑, 6,   RAS↓, 2,   Shh↓, 1,   Smo↓, 1,   SOX2↓, 2,   Src↓, 1,   STAT3↓, 8,   p‑STAT3↓, 1,   TCF↑, 1,   TCF-4↓, 2,   TOP1↓, 2,   TOP2↓, 3,   TumCG↓, 3,   Wnt↓, 10,  

Migration ⓘ

AntiAg↓, 1,   AP-1↓, 7,   AXL↓, 1,   Ca+2↑, 8,   CAFs/TAFs↓, 1,   CD31↓, 1,   Cdc42↑, 1,   CLDN2↓, 1,   CXCL12↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 10,   ER-α36↓, 1,   FAK↓, 5,   p‑FAK↓, 1,   Fibronectin↓, 2,   Ki-67↓, 4,   MET↓, 1,   MMP1↓, 3,   MMP13↓, 3,   MMP2↓, 17,   MMP3↓, 2,   MMP7↓, 7,   MMP9↓, 21,   MMP9↑, 1,   MMPs↓, 4,   N-cadherin↓, 6,   PDGF↓, 2,   PKCδ↓, 4,   Rho↓, 3,   RIP3↑, 1,   ROCK1↓, 2,   Slug↓, 2,   Snail?, 1,   Snail↓, 5,   TET1↓, 1,   TGF-β↓, 4,   TIMP1↓, 1,   TIMP2↓, 1,   TIMP2↑, 2,   TSP-1↑, 1,   TumCA↓, 1,   TumCI↓, 5,   TumCMig↓, 3,   TumCP↓, 6,   TumMeta↓, 9,   Twist↓, 4,   uPA↓, 25,   Vim↓, 8,   Zeb1↓, 2,   ZEB2↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 10,  

Angiogenesis & Vasculature ⓘ

angioG↓, 12,   ATF4↓, 1,   ATF4↑, 4,   EGFR↓, 8,   eNOS↓, 1,   Hif1a↓, 9,   NO↓, 1,   NO↑, 1,   PDGFR-BB↓, 1,   VEGF↓, 18,   VEGFR2↓, 5,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT1↓, 3,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD4+↓, 1,   COX2↓, 18,   CXCR4↓, 1,   IFN-γ↑, 1,   IKKα↓, 1,   IL1↓, 1,   IL10↓, 2,   IL1β↓, 1,   IL2↑, 2,   IL4↓, 1,   IL6↓, 4,   IL8↓, 3,   Inflam↓, 3,   JAK1↓, 1,   M2 MC↓, 1,   MCP1↓, 1,   MDSCs↓, 1,   NF-kB↓, 23,   NF-kB↑, 1,   p65↓, 1,   PD-L1↓, 1,   PGE2↓, 5,   TNF-α↓, 4,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 3,   CDK6↓, 6,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 6,   BioAv↑, 5,   BioAv↝, 2,   BioEnh↑, 1,   ChemoSen↑, 9,   Dose↑, 1,   Dose↝, 1,   eff↓, 1,   eff↑, 24,   eff↝, 2,   Half-Life↓, 4,   Half-Life↝, 2,   MDR1↓, 1,   RadioS↑, 4,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

AR↓, 3,   E6↓, 2,   E7↓, 2,   EGFR↓, 8,   Ferritin↓, 1,   HER2/EBBR2↓, 3,   IL6↓, 4,   Ki-67↓, 4,   Myc↓, 2,   PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 3,   AntiTum↑, 1,   cardioP↑, 2,   chemoP↑, 2,   chemoPv↑, 2,   hepatoP↑, 2,   neuroP↑, 2,   RenoP↑, 4,   toxicity↑, 1,   TumVol↓, 1,  
Total Targets: 342

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 9,   Catalase↑, 2,   GPx↑, 2,   GSH↑, 2,   HO-1↑, 1,   MDA↓, 1,   NRF2↑, 3,   Prx↑, 1,   ROS↓, 5,   SOD↑, 1,   SOD2↑, 1,  

Core Metabolism/Glycolysis ⓘ

p‑cMyc↑, 1,  

Cell Death ⓘ

Casp3?, 1,  

DNA Damage & Repair ⓘ

p16↓, 1,   P53↓, 1,  

Cell Cycle & Senescence ⓘ

P21↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↑, 1,  

Migration ⓘ

AntiAg↑, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 8,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 1,   hepatoP↑, 2,   neuroP↑, 4,   toxicity↓, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 1,  
Total Targets: 27

Scientific Paper Hit Count for: uPA, Urokinase plasminogen activator
10 Fisetin
3 Artemisinin
2 Ashwagandha(Withaferin A)
1 Apigenin (mainly Parsley)
1 Baicalein
1 Berberine
1 Chrysin
1 Propolis -bee glue
1 EGCG (Epigallocatechin Gallate)
1 Genistein (soy isoflavone)
1 Magnolol
1 Quercetin
1 Silymarin (Milk Thistle) silibinin
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:26  Cells:%  prod#:%  Target#:428  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page